Roots Analysis has done a detailed study on Prefilled Syringes, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 800+ page report, which features 800+ figures and 150+ tables, please visit https://www.rootsanalysis.com/reports/view_document/prefilled-syringes-market/284.html
Key Market Insights
- Presently, around 80 types of prefilled syringes are available in the market, and several companies claim to be engaged in the manufacturing of both glass and plastic variants of such versatile drug delivery solutions
- Over 140 drugs and vaccines have either been marketed or have undergone clinical investigation (since 2013) for delivery via prefilled syringes for the treatment of a variety of disease indications
- In order to gain a competitive edge in the market, prefilled syringe manufacturers are actively engaged in developing patient friendly products, with improved safety features and solutions
- The market is also characterized by the presence of many contract service providers, spread across the world, offering fill / finish services in prefilled syringes
- Several big pharma companies are actively engaged in strengthening their pipeline of injectable drugs across various therapeutic areas
- An evaluation of 280+ marketed and pipeline products revealed that a variety of drugs / product candidates are likely to be considered for administration via prefilled syringes in the near future, paving way for new partnerships
- The current market opportunity is well distributed across different therapeutic areas, molecule types and geographical regions; the market is likely to grow at a steady pace over the coming years
- Glass, single chamber prefilled syringes dominate the current market; however, the demand for plastic devices is anticipated to witness a relatively higher growth in the foreseen future
For more information, please visit https://www.rootsanalysis.com/reports/view_document/prefilled-syringes-market/284.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
Therefore, the use of technology can save time and money, while providing a far better understanding of the relationships between different formulations and processes parameters.Key Drivers, Restraints, and Opportunities of AI in Pharma and Biotech MarketAdoption of artificial intelligence (AI) in the drug discovery market in developing regions such as APAC is increasing, thanks to the expansion of pharmaceutical industries by collaborating with other industries and rise in demand to reduce drug discovery time.
Furthermore, the expansion of biotechnology industries is estimated to offer significant opportunities for the market.An estimated 50% of U.S. citizens are affected by at least one chronic condition; consequently, the pharmaceutical segment of the healthcare industry is projected to be positively impacted by the expected trend of AI adoption.All top 10 so-called giant pharma companies (namely Novartis, Roche, Pfizer, Merck, AstraZeneca, GlaxoSmithKline, Sanofi, Abbvie, Bristol-Myers Squibb, and Johnson & Johnson) have either expressly collaborated with or acquired AI technologies to take advantage of the opportunities AI brings to the table.
Industry leaders are presently focused on the development of more efficient methods, and machine learning is emerging as a possible solution.The current machine learning initiatives of the top five pharmaceutical and biotechnology companies reveal trends within the following areas:Digital coaching solutions – Utilization of web-based technologies to simulate one-on-one coaching sessions so that all patients can have the benefit of a uniquely devised medication program.For instance: Johnson & Johnson’s Patient Athlete programPersonalized medicine – Personalized medicine, also called precision medicine, maybe a medical model that separates people into different groups—with medical decisions, practices, interventions, and/or products being tailored to the individual patient supported their predicted response or risk of disease.For instance.
Unlike other applications within healthcare facilities, drug discovery seems to own a clearer path to adoption.Recently, robots became more collaborative with humans and are more easily trained by moving them through the desired task.
Over time, it seems likely that an equivalent improvement in intelligence that we have seen in other areas of AI would be incorporated into physical robots.Surgical robots initially approved in the U.S. in 2000, provided ‘superpowers’ to surgeons, improving their ability to examine, create precise and minimally invasive incisions, and stitch wounds.
Common surgical procedures using robotic surgery include gynecologic surgery, prostate surgery, and head and neck surgery.Pre Book Ai In Pharma And Biotech Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=79399=S North America to Capture Major Share of Global Market of AI in Pharma & BiotechNorth America is expected to account for a major share of the global market of AI in Pharma and Biotech due to the high prevalence of chronic diseases among the population.
Softcon Systems brings you automation solutions specific to the pharmaceutical industry – we will work with you to develop and implement ideal solutions specific to your requirements.
Automation at every point of the value chain will enable the pharma companies to get pharmaceuticals from the lab to the patient more quickly.We design systems that help pharmaceutical and biotech companies to achieve operational excellence, reduce time to market and meet all industry standards and regulations.
